Severe Acute Respiratory Syndrome Coronavirus 2 Clinical Syndromes and Predictors of Disease Severity in Hospitalized Children and Youth
Fernandes DM, Oliveira CR, Guerguis S, Eisenberg R, Choi J, Kim M, Abdelhemid A, Agha R, Agarwal S, Aschner JL, Avner JR, Ballance C, Bock J, Bhavsar SM, Campbell M, Clouser KN, Gesner M, Goldman DL, Hammerschlag MR, Hymes S, Howard A, Jung HJ, Kohlhoff S, Kojaoghlanian T, Lewis R, Nachman S, Naganathan S, Paintsil E, Pall H, Sy S, Wadowski S, Zirinsky E, Cabana MD, Herold BC, Consortium T. Severe Acute Respiratory Syndrome Coronavirus 2 Clinical Syndromes and Predictors of Disease Severity in Hospitalized Children and Youth. The Journal Of Pediatrics 2020, 230: 23-31.e10. PMID: 33197493, PMCID: PMC7666535, DOI: 10.1016/j.jpeds.2020.11.016.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBiomarkersChildChild, PreschoolConnecticutCOVID-19C-Reactive ProteinFemaleHospitalizationHumansHypoxiaInfantIntensive Care UnitsLymphocyte CountMaleMultivariate AnalysisNew JerseyNew YorkPediatric ObesityProcalcitoninProspective StudiesRetrospective StudiesSeverity of Illness IndexSystemic Inflammatory Response SyndromeTroponinYoung AdultConceptsSARS-CoV-2 infectionRespiratory diseaseDisease severityClinical featuresAcute SARS-CoV-2 infectionGreater C-reactive proteinLow absolute lymphocyte countFuture prognostic toolAbsolute lymphocyte countTime of hospitalizationC-reactive proteinIntensive care unitSevere respiratory diseaseNon-Hispanic blacksRace/ethnicitySevere MISInflammatory syndromeLymphocyte countHospital admissionPediatric patientsCare unitMultivariable analysisProspective studyHospitalized childrenClinical managementMulticenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2
Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, Yarbrough A, Abzug MJ, MacBrayne CE, Soma VL, Dulek DE, Vora SB, Waghmare A, Wolf J, Olivero R, Grapentine S, Wattier RL, Bio L, Cross SJ, Dillman NO, Downes KJ, Oliveira CR, Timberlake K, Young J, Orscheln RC, Tamma PD, Schwenk HT, Zachariah P, Aldrich ML, Goldman DL, Groves HE, Rajapakse NS, Lamb GS, Tribble AC, Hersh AL, Thorell EA, Denison MR, Ratner AJ, Newland JG, Nakamura MM. Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. Journal Of The Pediatric Infectious Diseases Society 2020, 10: 34-48. PMID: 32918548, PMCID: PMC7543452, DOI: 10.1093/jpids/piaa115.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdenosine MonophosphateAlanineAntiviral AgentsChildCOVID-19COVID-19 Drug TreatmentEvidence-Based MedicineHumansImmunocompromised HostRisk FactorsSeverity of Illness IndexSystemic Inflammatory Response SyndromeConceptsMechanical ventilationCOVID-19Pediatric infectious disease physiciansInvasive mechanical ventilationSupplemental oxygen requirementInfectious disease physiciansUse of hydroxychloroquineUse of remdesivirNoninvasive mechanical ventilationUse of antiviralsCoronavirus disease 2019Series of teleconferencesPotential antiviral activityLopinavir-ritonavirCritical illnessDisease physiciansMost patientsSupportive careMembrane oxygenationPediatric patientsAntiviral therapyMild courseSevere illnessIll childrenClinical trials